 A year after I-Mab NASDAQ: IMAB made headlines with its 2.9 billion deal licensing a CD47 drug to AbbVie Inc NYSE: ABBV, the biotech is reportedly holding talks with big pharma players about partnerships and potential investment. Bloomberg broke the news of the early talks with global biopharma companies citing people familiar with the matter. 